Poland· PL-100150050
Maść Tormentiolowa Herbapol
A medicinal product containing tormentillae extractum fluidum +ammonii bituminosulfonas + zinci oxidum, registered in Poland by Poznańskie Zakłady Zielarskie "Herbapol" S.A..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Tormentillae extractum fluidum +Ammonii bituminosulfonas + Zinci oxidum
- Manufacturer
- Poznańskie Zakłady Zielarskie "Herbapol" S.A.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990022823
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e06e5db5-a89a-4f0f-89da-b2335807a011 GET /v1/drugs/e06e5db5-a89a-4f0f-89da-b2335807a011?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Maść",
"source": "urpl",
"strength": "(30 mg + 20 mg + 200 mg)/g",
"packaging": "05909990022823 ¦ OTC ¦ 51665\n1 tuba 20 g",
"substance": "Tormentillae extractum 3 % + Ammonii bituminosulfonas 2 % + Zinci oxidum 20 % + etanol 50% -",
"common_name": "Tormentillae extractum fluidum +Ammonii bituminosulfonas + Zinci oxidum",
"pl_product_id": "100150050",
"pozwolenie_nr": "IL-2904/LN",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about tormentillae extractum fluidum +ammonii bituminosulfonas + zinci oxidum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.